Price$1.29-0.02 (-1.90%)
01:45 PM03:30 PM
News · 26 weeks33+150%
2026-04-192026-10-11
Mix1190d
- Other7(64%)
- SEC Filings3(27%)
- Analyst1(9%)
Latest news
25 items- ANALYSTLeerink Partners resumed coverage on Equillium with a new price targetLeerink Partners resumed coverage of Equillium with a rating of Outperform and set a new price target of $6.00
- PREquillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology ConferenceLA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in a poster at the 50th Anniversary La Jolla Immunology Conference, taking place October 6-8, 2026 in La Jolla, California. "These data provide additional insight into the multi-modal activity of EQ504, demonstrating coordinated effects across epithelial and immune compartments that preserve barrier integrity while resolving inflammation," said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. "We believe these
- SECSEC Form 8-K filed by Equillium Inc.8-K - Equillium, Inc. (0001746466) (Filer)
- PREquillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of EQ504 in healthy subjects LA JOLLA, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that the Company has received Human Research Ethics Committee (HREC) approval and clearance from the Therapeutic Goods Administration (TGA) in Australia under the Clinical Trial Not
- PREquillium Announces Poster Presentations at the 7th International AHR ConferenceLA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in two posters at the 7th International AHR Conference, taking place September 29 to October 2, 2026, in Porto, Portugal. "These studies further characterize the multi-modal activity of EQ504, including its effects on epithelial barrier repair and key immune pathways involved in inflammation," said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. "Together, the findings add to the growing body of preclinical
- PREquillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation ForumLA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. A live webcast of the fireside chat may also be accessed on the Events & Presentations page, located under the Investor Relations section on equilliumbio.com. A replay of the webcast will be availa
- PREquillium to Participate in Upcoming Investor ConferencesLA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Company Presentation & 1x1 MeetingsDate: Monday, September 14, 2026Time: 11:00 AM EDT Members of the Equillium management team will be available to meet with investors who are registered to attend t
- SECSEC Form 10-Q filed by Equillium Inc.10-Q - Equillium, Inc. (0001746466) (Filer)
- SECEquillium Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Equillium, Inc. (0001746466) (Filer)
- PREquillium Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsPhase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update highlighting continued progress in support of EQ504, its potent and selective aryl hydrocarbon receptor (AhR) modulator. "We continue to make mean
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Equillium Inc.SCHEDULE 13G/A - Equillium, Inc. (0001746466) (Subject)
- ANALYSTPiper Sandler initiated coverage on EquilliumPiper Sandler initiated coverage of Equillium with a rating of Overweight
- INSIDERSr. Vice President and COO Zedelmayer Christine exercised 14,584 shares at a strike of $0.79 and sold $42,737 worth of shares (14,584 units at $2.93) as part of a pre-agreed trading plan (SEC Form 4)4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERPresident and CSO Connelly Stephen sold $723,830 worth of shares (230,975 units at $3.13), decreasing direct ownership by 23% to 762,025 units (SEC Form 4)4 - Equillium, Inc. (0001746466) (Issuer)
- PREquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 145,000 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price per share equal to $3.08, Equ
- INSIDERPrincipal Accounting Officer Tom Penny sold $191,750 worth of shares (65,000 units at $2.95) as part of a pre-agreed trading plan and exercised 65,000 shares at a strike of $0.79 (SEC Form 4)4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSEC Form 4 filed by Director Demski Martha J4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSEC Form 4 filed by Director Pruzanski Mark4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSEC Form 4 filed by CHAIRMAN Bradbury Daniel4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSr. Vice President and COO Zedelmayer Christine sold $267,209 worth of shares (95,833 units at $2.79) as part of a pre-agreed trading plan and exercised 95,833 shares at a strike of $0.77 (SEC Form 4)4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcdermott Charles Douglas4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSEC Form 4 filed by Director Troupin Barbara4 - Equillium, Inc. (0001746466) (Issuer)
- SECSEC Form 8-K filed by Equillium Inc.8-K - Equillium, Inc. (0001746466) (Filer)
- PREquillium to Participate in the 2026 Jefferies Global Healthcare ConferenceLA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders. For more information, visit www.equilliumbio.com.
- ANALYSTEquillium upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Equillium from Market Perform to Outperform and set a new price target of $6.00
EQ FAQ
7 questionsWhat does Equillium Inc. do?
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium...Where does EQ stock trade?
Equillium Inc. (EQ) is listed on NASDAQ.What sector and industry is EQ in?
Equillium Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Equillium Inc. go public?
Equillium Inc. (EQ) completed its IPO in 2018.What are analysts saying about EQ?
Equillium Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $600.00 price target on 2026-10-12. Recent price targets range from $600.00 to $1200.00.What companies are similar to EQ?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EQ side-by-side with any of them on Quantisnow.How can I track EQ on Quantisnow?
Quantisnow aggregates Equillium Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EQ to receive live email and push alerts on every new disclosure.